Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
U.S. stocks traded mostly higher, with the Dow Jones index gaining around 80 points on Wednesday.
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) fell sharply during Wednesday’s session after the company announced a clinical program update for LN-145 TIL therapy in non-small lung cancer (NSCLC).
The FDA placed a clinical hold on the IOV-LUN-202 trial on December 22, 2023, in response to a recently reported Grade 5 (fatal) serious adverse event potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen.
Iovance Biotherapeutics shares dipped 20.4% to $7.07 on Wednesday.
Here are some other big stocks recording gains in today’s session.
Now Read This: Ethereum Moves Higher; Bitcoin SV Emerges As Top Gainer
Posted In: CCG CGC GHG IHT IOVA LNZA LTH NIO NTES NUKK SKIN VEL